HEADER HYDROLASE/HYDROLASE INHIBITOR 30-OCT-02 1N49 TITLE VIABILITY OF A DRUG-RESISTANT HIV-1 PROTEASE VARIANT: STRUCTURAL TITLE 2 INSIGHTS FOR BETTER ANTI-VIRAL THERAPY COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B, C, D; COMPND 4 SYNONYM: RETROPEPSIN; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: TAP106; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PEN18 KEYWDS HIV-1 PROTEASE, DRUG RESISTANCE, SUBSTRATE RECOGNITION, INHIBITOR KEYWDS 2 BINDING, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING,C.A.SCHIFFER REVDAT 6 14-FEB-24 1N49 1 REMARK REVDAT 5 27-OCT-21 1N49 1 REMARK SEQADV REVDAT 4 11-OCT-17 1N49 1 REMARK REVDAT 3 13-JUL-11 1N49 1 VERSN REVDAT 2 24-FEB-09 1N49 1 VERSN REVDAT 1 07-JAN-03 1N49 0 JRNL AUTH M.PRABU-JEYABALAN,E.A.NALIVAIKA,N.M.KING,C.A.SCHIFFER JRNL TITL VIABILITY OF A DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS JRNL TITL 2 TYPE 1 PROTEASE VARIANT: STRUCTURAL INSIGHTS FOR BETTER JRNL TITL 3 ANTIVIRAL THERAPY JRNL REF J.VIROL. V. 77 1306 2003 JRNL REFN ISSN 0022-538X JRNL PMID 12502847 JRNL DOI 10.1128/JVI.77.2.1306-1315.2003 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.PRABU-JEYABALAN,E.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL HOW DOES A SYMMETRIC DIMER RECOGNIZE AN ASYMMETRIC REMARK 1 TITL 2 SUBSTRATE? A SUBSTRATE COMPLEX OF HIV-1 PROTEASE REMARK 1 REF J.MOL.BIOL. V. 301 1207 2000 REMARK 1 REFN ISSN 0022-2836 REMARK 1 DOI 10.1006/JMBI.2000.4018 REMARK 1 REFERENCE 2 REMARK 1 AUTH M.PRABU-JEYABALAN,E.NALIVAIKA,C.A.SCHIFFER REMARK 1 TITL SUBSTRATE SHAPE DETERMINES SPECIFICITY OF RECOGNITION FOR REMARK 1 TITL 2 HIV-1 PROTEASE: ANALYSIS OF CRYSTAL STRUCTURES OF SIX REMARK 1 TITL 3 SUBSTRATE COMPLEXES REMARK 1 REF STRUCTURE V. 10 369 2002 REMARK 1 REFN ISSN 0969-2126 REMARK 1 DOI 10.1016/S0969-2126(02)00720-7 REMARK 1 REFERENCE 3 REMARK 1 AUTH N.M.KING,L.MELNICK,M.PRABU-JEYABALAN,E.A.NALIVAIKA,S.S.YANG, REMARK 1 AUTH 2 Y.GAO,X.NIE,C.ZEPP,D.L.HEEFNER,C.A.SCHIFFER REMARK 1 TITL LACK OF SYNERGY FOR INHIBITORS TARGETING A MULTI-DRUG REMARK 1 TITL 2 RESISTANT HIV-1 PROTEASE REMARK 1 REF PROTEIN SCI. V. 11 418 2002 REMARK 1 REFN ISSN 0961-8368 REMARK 1 DOI 10.1110/PS.2520102 REMARK 1 REFERENCE 4 REMARK 1 AUTH D.J.KEMPF,K.C.MARSH,J.F.DENISSEN,E.MCDONALD,S.VASAVANONDA, REMARK 1 AUTH 2 C.A.FLENTGE,B.E.GREEN,L.FINO,C.H.PARK,X.KONG,N.E.WIDEBURG, REMARK 1 AUTH 3 A.SALDIVAR,L.RUIZ,W.M.KATI,H.L.SHAM,T.ROBINS,K.D.STEWART, REMARK 1 AUTH 4 A.HSU,J.J.PLATTNER,J.M.LEONARD,D.W.NORBECK REMARK 1 TITL ABT-538 IS A POTENT INHIBITOR OF HUMAN IMMUNODEFICIENCY REMARK 1 TITL 2 VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS REMARK 1 REF PROC.NATL.ACAD.SCI.USA V. 92 2484 1995 REMARK 1 REFN ISSN 0027-8424 REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 71.2 REMARK 3 NUMBER OF REFLECTIONS : 13097 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.223 REMARK 3 FREE R VALUE : 0.284 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1085 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.20 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.28 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 66.00 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3200 REMARK 3 BIN FREE R VALUE : 0.3700 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2844 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 100 REMARK 3 SOLVENT ATOMS : 28 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.400 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 28.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.150 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NCS RESTRAINTS IMPOSED BETWEEN THE REMARK 3 DIMERS (BUT NOT WITHIN THE DIMERS) TO IMPROVE OBSERVABLES TO REMARK 3 PARAMETER RATIO. REMARK 4 REMARK 4 1N49 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 12-NOV-02. REMARK 100 THE DEPOSITION ID IS D_1000017499. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 07-AUG-01 REMARK 200 TEMPERATURE (KELVIN) : 200 REMARK 200 PH : 6.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : YALE MIRRORS REMARK 200 OPTICS : YALE MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : R-AXIS REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 13097 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 71.2 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.06400 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 7.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.28 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.27000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1F7A REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.59 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.14 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: SODIUM PHOSPHATE, SODIUM CITRATE, REMARK 280 AMMONIUM SULPHATE, PH 6.2, VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 30.67500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4970 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -42.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5030 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -39.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ILE A 3 CG1 CG2 CD1 REMARK 470 ARG A 14 CG CD NE CZ NH1 NH2 REMARK 470 GLN A 18 CG CD OE1 NE2 REMARK 470 LEU A 19 CG CD1 CD2 REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 GLU A 65 CG CD OE1 OE2 REMARK 470 LYS A 70 CG CD CE NZ REMARK 470 GLN A 92 CG CD OE1 NE2 REMARK 470 GLN B 2 CG CD OE1 NE2 REMARK 470 LYS B 7 CG CD CE NZ REMARK 470 ARG B 14 CG CD NE CZ NH1 NH2 REMARK 470 GLN B 18 CG CD OE1 NE2 REMARK 470 LEU B 19 CG CD1 CD2 REMARK 470 MET B 36 CG SD CE REMARK 470 ASN B 37 CG OD1 ND2 REMARK 470 LYS B 41 CG CD CE NZ REMARK 470 LYS B 43 CG CD CE NZ REMARK 470 LYS B 45 CG CD CE NZ REMARK 470 GLN B 61 CG CD OE1 NE2 REMARK 470 LYS B 70 CG CD CE NZ REMARK 470 ARG B 87 CG CD NE CZ NH1 NH2 REMARK 470 GLN C 2 CG CD OE1 NE2 REMARK 470 ILE C 3 CG1 CG2 CD1 REMARK 470 LYS C 7 CG CD CE NZ REMARK 470 ARG C 14 CG CD NE CZ NH1 NH2 REMARK 470 ILE C 15 CG1 CG2 CD1 REMARK 470 LEU C 19 CG CD1 CD2 REMARK 470 ASN C 37 CG OD1 ND2 REMARK 470 LYS C 41 CG CD CE NZ REMARK 470 LYS C 43 CG CD CE NZ REMARK 470 LYS C 45 CG CD CE NZ REMARK 470 LYS C 55 CG CD CE NZ REMARK 470 GLN C 61 CG CD OE1 NE2 REMARK 470 LYS C 70 CG CD CE NZ REMARK 470 ARG D 14 CG CD NE CZ NH1 NH2 REMARK 470 GLU D 34 CG CD OE1 OE2 REMARK 470 GLU D 35 CG CD OE1 OE2 REMARK 470 LYS D 41 CG CD CE NZ REMARK 470 LYS D 43 CG CD CE NZ REMARK 470 LYS D 45 CG CD CE NZ REMARK 470 LYS D 55 CG CD CE NZ REMARK 470 GLU D 65 CG CD OE1 OE2 REMARK 470 ILE D 66 CG1 CG2 CD1 REMARK 470 LYS D 70 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O ASP B 29 OD1 ASN B 88 2.10 REMARK 500 O ASP C 29 OD1 ASN C 88 2.13 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 35 123.91 -27.27 REMARK 500 TRP A 42 136.18 -175.38 REMARK 500 CYS A 67 70.25 58.61 REMARK 500 MET B 36 121.63 -179.14 REMARK 500 PRO B 79 80.12 -63.93 REMARK 500 GLN C 2 38.83 -146.52 REMARK 500 GLU D 35 159.80 -36.75 REMARK 500 MET D 36 -138.58 -177.18 REMARK 500 TRP D 42 148.01 -172.24 REMARK 500 PRO D 79 30.02 -58.70 REMARK 500 REMARK 500 REMARK: NULL REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE INHIBITOR REMARK 630 MOLECULE NAME: RITONAVIR REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 RIT B 301 REMARK 630 RIT D 401 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: 013 015 VAL 019 REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE RIT B 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE RIT D 401 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1F7A RELATED DB: PDB REMARK 900 INACTIVE WILD-TYPE HIV PROTEASE (D25N) COMPLEXED WITH ITS GAG REMARK 900 SUBSTRATE PEPTIDE, CA-P2 REMARK 900 RELATED ID: 1HXW RELATED DB: PDB REMARK 900 HIV-1 PROTEASE DIMER COMPLEXED WITH (RITONAVIR) A-84538 DBREF 1N49 A 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1N49 B 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1N49 C 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1N49 D 1 99 UNP P03369 POL_HV1A2 57 155 SEQADV 1N49 LYS A 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1N49 ASN A 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQADV 1N49 ALA A 82 UNP P03369 VAL 138 ENGINEERED MUTATION SEQADV 1N49 LYS B 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1N49 ASN B 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQADV 1N49 ALA B 82 UNP P03369 VAL 138 ENGINEERED MUTATION SEQADV 1N49 LYS C 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1N49 ASN C 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQADV 1N49 ALA C 82 UNP P03369 VAL 138 ENGINEERED MUTATION SEQADV 1N49 LYS D 7 UNP P03369 GLN 63 ENGINEERED MUTATION SEQADV 1N49 ASN D 25 UNP P03369 ASP 81 ENGINEERED MUTATION SEQADV 1N49 ALA D 82 UNP P03369 VAL 138 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 C 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 C 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 C 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 C 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 C 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 C 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 C 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 C 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 D 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 D 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASN THR SEQRES 3 D 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 D 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 D 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 D 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 D 99 PRO THR PRO ALA ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 D 99 GLN ILE GLY CYS THR LEU ASN PHE HET RIT B 301 50 HET RIT D 401 50 HETNAM RIT RITONAVIR HETSYN RIT A-84538 FORMUL 5 RIT 2(C37 H48 N6 O5 S2) FORMUL 7 HOH *28(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 86 ILE B 93 1 8 HELIX 3 3 GLY C 86 ILE C 93 1 8 HELIX 4 4 GLY D 86 ILE D 93 1 8 SHEET 1 A 3 GLN A 2 ILE A 3 0 SHEET 2 A 3 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 3 THR A 96 ASN A 98 -1 O THR A 96 N ASN B 98 SHEET 1 B 9 LEU A 10 ILE A 15 0 SHEET 2 B 9 GLN A 18 LEU A 24 -1 N GLN A 18 O ILE A 15 SHEET 3 B 9 ILE A 84 ILE A 85 1 N ILE A 85 O LEU A 23 SHEET 4 B 9 VAL A 32 GLU A 34 -1 O VAL A 32 N ILE A 84 SHEET 5 B 9 LYS A 70 GLY A 78 1 O LEU A 76 N LEU A 33 SHEET 6 B 9 GLY A 52 ILE A 66 -1 N ARG A 57 O VAL A 77 SHEET 7 B 9 LYS A 43 GLY A 49 -1 O LYS A 43 N GLN A 58 SHEET 8 B 9 GLY A 52 ILE A 66 -1 O GLY A 52 N GLY A 49 SHEET 9 B 9 LEU A 10 ILE A 15 -1 O ARG A 14 N GLU A 65 SHEET 1 C 8 LYS B 43 GLY B 48 0 SHEET 2 C 8 PHE B 53 ILE B 66 -1 N ILE B 54 O ILE B 47 SHEET 3 C 8 LEU B 10 ILE B 15 -1 O ARG B 14 N GLU B 65 SHEET 4 C 8 GLN B 18 LEU B 24 -1 N GLN B 18 O ILE B 15 SHEET 5 C 8 ILE B 84 ILE B 85 1 N ILE B 85 O LEU B 23 SHEET 6 C 8 THR B 31 LEU B 33 -1 O VAL B 32 N ILE B 84 SHEET 7 C 8 ILE B 72 VAL B 77 1 O THR B 74 N THR B 31 SHEET 8 C 8 PHE B 53 ILE B 66 -1 O ARG B 57 N VAL B 77 SHEET 1 D 8 LYS C 43 GLY C 48 0 SHEET 2 D 8 PHE C 53 ILE C 66 -1 N ILE C 54 O ILE C 47 SHEET 3 D 8 LEU C 10 ILE C 15 -1 O ARG C 14 N GLU C 65 SHEET 4 D 8 GLN C 18 LEU C 24 -1 O GLN C 18 N ILE C 15 SHEET 5 D 8 ILE C 84 ILE C 85 1 N ILE C 85 O LEU C 23 SHEET 6 D 8 THR C 31 GLU C 34 -1 O VAL C 32 N ILE C 84 SHEET 7 D 8 HIS C 69 GLY C 78 1 O THR C 74 N THR C 31 SHEET 8 D 8 PHE C 53 ILE C 66 -1 O ARG C 57 N VAL C 77 SHEET 1 E 3 THR D 96 ASN D 98 0 SHEET 2 E 3 THR C 96 ASN C 98 -1 O THR C 96 N ASN D 98 SHEET 3 E 3 GLN D 2 ILE D 3 -1 N ILE D 3 O LEU C 97 SHEET 1 F 8 LYS D 43 GLY D 49 0 SHEET 2 F 8 GLY D 52 ILE D 66 -1 O GLY D 52 N GLY D 49 SHEET 3 F 8 LEU D 10 ILE D 15 -1 O ARG D 14 N GLU D 65 SHEET 4 F 8 GLN D 18 LEU D 24 -1 N GLN D 18 O ILE D 15 SHEET 5 F 8 ILE D 84 ILE D 85 1 N ILE D 85 O LEU D 23 SHEET 6 F 8 VAL D 32 GLU D 34 -1 O VAL D 32 N ILE D 84 SHEET 7 F 8 LYS D 70 GLY D 78 1 O LEU D 76 N LEU D 33 SHEET 8 F 8 GLY D 52 ILE D 66 -1 N ARG D 57 O VAL D 77 SITE 1 AC1 19 ASN A 25 GLY A 27 ALA A 28 ASP A 29 SITE 2 AC1 19 GLY A 48 GLY A 49 ILE A 50 PRO A 81 SITE 3 AC1 19 ILE A 84 HOH A 105 ARG B 8 ASN B 25 SITE 4 AC1 19 GLY B 27 ASP B 30 VAL B 32 GLY B 49 SITE 5 AC1 19 PRO B 81 ILE B 84 HOH B 303 SITE 1 AC2 21 ARG C 8 ASN C 25 GLY C 27 ASP C 30 SITE 2 AC2 21 VAL C 32 ILE C 47 GLY C 49 ILE C 50 SITE 3 AC2 21 PRO C 81 ILE C 84 ASN D 25 GLY D 27 SITE 4 AC2 21 ALA D 28 ASP D 29 GLY D 48 GLY D 49 SITE 5 AC2 21 ILE D 50 PRO D 81 ILE D 84 HOH D 402 SITE 6 AC2 21 HOH D 403 CRYST1 51.620 61.350 59.040 90.00 81.20 90.00 P 1 21 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019372 0.000000 -0.002999 0.00000 SCALE2 0.000000 0.016300 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017139 0.00000